Highlights From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium.
نویسنده
چکیده
منابع مشابه
The science of checkpoint inhibition in kidney cancer.
Immunotherapy has offered the hope of a cancer cure for 100 years, according to Gordon J. Freeman, PhD. Although a cure remains elusive, “the door is now open,” Dr Freeman said. Programmed death 1 (PD-1) inhibitors have provided “a good foundation to build upon” for the treatment of kidney cancer and other cancers. Dr Freeman, who is a professor of medicine at Harvard Medical School in Boston, ...
متن کاملProstate cancer: evolution or revolution?
In this issue of Journal of Clinical Oncology, we present a special series on prostate cancer that illustrates how our understanding of the biology and therapy of this disease has changed over the last few years. This series comes on the heels of the 2011 Genitourinary Cancers Symposium (held February 17 to 19, 2011, in Orlando, FL), jointly sponsored by the American Society of Clinical Oncolog...
متن کاملIdentification of prognostic and predictive markers in pancreatic adenocarcinoma. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Pancreatic cancer remains a significant cause of morbidity and mortality. While increasing treatment options have improved outcomes for many patients, they have also complicated decision-making for treatment. Unfortunately, most patients with pancreatic cancer die from their disease. Prognostic and predictive markers could play a role to improve treatment by identifying patients who may or may ...
متن کاملMeeting Report Cancer Immunotherapy Highlights from the 2014 ASCO Meeting
The promise of cancer immunotherapy was validated officially in March 2011 when the FDA approved Yervoy (ipilimumab; Bristol-Myers Squibb) for the treatment of unresectable ormetastatic melanoma. The approval was based on results of a randomized, double-blind clinical trial establishing that ipilimumab (a humanized antiCTLA-4 monoclonal antibody) treatment extended the overall survival of patie...
متن کاملCancer immunotherapy highlights from the 2014 ASCO Meeting.
The promise of cancer immunotherapy was validated officially in March 2011 when the FDA approved Yervoy (ipilimumab; Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma. The approval was based on results of a randomized, double-blind clinical trial establishing that ipilimumab (a humanized anti-CTLA-4 monoclonal antibody) treatment extended the overall survival of pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical advances in hematology & oncology : H&O
دوره 14 3 شماره
صفحات -
تاریخ انتشار 2016